Expert veterinary care for every stage of your pet’s life.
Emergency: 617-522-7282
Poison Control: 888-426-4435
Bringing pets and people together.
Advocate for animals, volunteer, or get help for your pet with our compassionate community services.
Introduction
Canine cardiac tumors are most often divided into two broad categories: right atrial hemangiosarcoma (HSA) and heart base tumors (HBTs), the latter of which are most commonly chemodectomas. Both are clinically significant, but they differ markedly in their biology, clinical presentation, and patient outcomes. In both settings, radiation therapy is becoming an increasingly valuable tool, not only for cytoreduction, but also for its hemostatic properties.
Right Atrial Hemangiosarcoma
Right atrial hemangiosarcoma is the most common primary cardiac tumor in dogs. It typically arises in the right atrium or auricular appendage, and it may appear either as a discrete nodule or a more infiltrative lesion. Clinical signs vary depending on stage. Early in the course, dogs may only show vague lethargy, weakness, or coughing. As the tumor progresses, however, more dramatic presentations are common, including collapse, dyspnea, and acute hemorrhagic pericardial effusion. In many cases, tamponade and cardiogenic shock are the events that bring patients to veterinary attention.
Diagnosis relies heavily on echocardiography, which is both sensitive and specific for identifying these lesions. Pericardial fluid cytology is rarely diagnostic, with the exception of in cases of cardiac lymphoma (extremely rare).
Unfortunately, the prognosis with traditional therapies is very poor. Without intervention, survival may be measured in days. Pericardiectomy can extend survival to two to three months, and the combination of surgery with chemotherapy offers a median survival of four to six months. Chemotherapy alone after resection may increase survival to approximately five or six months, but in all cases, metastatic spread and recurrent bleeding remain major obstacles.
Radiation therapy is being used more frequently to address these limitations. The rationale is twofold: to reduce tumor bulk and stabilize fragile vasculature to decrease bleeding. A pilot study using a single, 12-Gy fraction demonstrated significant reduction in the need for pericardiocentesis, with a median survival of about 79 days. More advanced protocols, such as hypofractionated IMRT in combination with vinblastine and propranolol, achieved resolution of pericardial effusions in all treated dogs, with responses ranging from complete remission to stable disease and a median survival of 326 days. Larger retrospective series show similar findings, with pericardiocentesis frequency dropping by over 80% and a median survival of 137 days. Importantly, when CT guidance is used, adverse events are less frequent. Taken together, these studies suggest that radiation, especially when combined with systemic therapy, can extend survival into the many-month to nearly-one-year range, while improving patient stability and comfort.
Heart Base Tumors (HBTs)
While hemangiosarcoma is aggressive, fast-growing, and highly metastatic, HBTs behave very differently. Chemodectomas, the most common HBTs, tend to be slow-growing, more indolent, and often discovered incidentally. The clinical presentations also differ: Hemangiosarcoma usually presents with acute collapse and tamponade, whereas HBTs are more likely to cause chronic signs from mechanical compression, such as coughing, dyspnea, exercise intolerance, or syncope. These biological differences also shift the therapeutic goals. Hemangiosarcoma demands crisis stabilization and palliation of bleeding, while HBTs are better suited to long-term local control strategies.
Chemodectoma
HBTs are typically located at the root of the aorta and pulmonary arteries, near the carotid bifurcation and jugular veins. They are usually encapsulated, homogeneous, space-occupying masses. Clinical signs reflect compression of adjacent structures and include coughing, respiratory distress, or exercise intolerance. Metastasis is reported but occurs in only about 20% of cases.
Surgical removal is often not feasible due to the tumor’s location, so radiation therapy is the treatment of choice. Both stereotactic body radiation therapy (SBRT) and conventional fractionated radiation therapy (CFRT) have shown excellent results. In a study using SBRT, the median survival was 404 days, with most dogs achieving either partial response or stable disease. In another series comparing SBRT and CFRT, overall median survival was 785 days. Dogs treated with CFRT lived a median of 817 days, while those receiving SBRT had a shorter but still meaningful median survival of about 414 days. Side effects are generally mild, though arrhythmias, congestive heart failure, or sudden death have been reported in rare cases. Overall, radiation is well tolerated and provides durable tumor control in this population.
Hemostatic Role of Radiation
Beyond tumor shrinkage, radiation has important hemostatic effects. By inducing fibrosis, promoting platelet adhesion, and creating pro-thrombotic changes in tumor vasculature, it can reduce or even stop hemorrhage. In human oncology, palliative radiation is widely used to manage bleeding in gastrointestinal and other cancers. This same principle is increasingly recognized in veterinary oncology, especially in the management of cardiac hemangiosarcoma, where stabilization of vascular integrity is just as important as tumor cytoreduction.
Conclusion
Right atrial hemangiosarcoma remains one of the most aggressive cardiac tumors, with a guarded to poor prognosis. However, radiation therapy, particularly when combined with chemotherapy, can extend survival significantly and improve quality of life by reducing bleeding and stabilizing patients. Heart base tumors, in contrast, are much more indolent, and radiation therapy provides excellent long-term local control, often extending survival beyond a year. In both contexts, radiation plays a dual role — tumor cytoreduction and hemostasis — that is central to management.
Optimal outcomes require a multidisciplinary approach, bringing together cardiology, oncology, and advanced imaging to deliver tailored, evidence-based care for these challenging but increasingly manageable diseases.
References
